Avadel Pharmaceuticals
Avadel Pharmaceuticals plc
16640 Chesterfield Grove Road, Suite 200
Chesterfield, MO 63005
Phone: (800) 893-5516Website: https://www.avadel.com/Careers: www.avadel.com/careers
Latest news
- FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
1 May 2023 - Avadel Pharmaceuticals Requests Final FDA Approval for Lumryz (sodium oxybate) Extended-Release Oral Suspension
2 March 2023 - Avadel Pharmaceuticals Announces Tentative Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension
19 July 2022 - Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians
11 March 2022 - Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
1 March 2021 - FDA Approves Nouress (cysteine hydrochloride) Injection for Treating Neonate Patients Requiring Total Parenteral Nutrition (TPN)
16 December 2019 - Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019
8 August 2019 - Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001
22 May 2019
Drugs Associated with Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Lumryz
Generic name: sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
1 review | 10 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
